{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:34Z","timestamp":1791568834499,"version":"4.3.4"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"name":"International Centers for Precision Oncology (ICPO) Foundation"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Peptide receptor radionuclide therapy (PRRT) offers a promising treatment option by targeting the high density of somatostatin receptors overexpressed in meningiomas. The objective of this study aimed to evaluate the long-term outcome of PRRT in patients with refractory meningioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Eighteen patients with refractory meningioma, presenting with progression or recurrence despite surgery or radiotherapy or having inoperable tumors and lack of other therapeutic options, received PRRT with\n                      <jats:sup>177<\/jats:sup>\n                      Lu-labeled or\n                      <jats:sup>90<\/jats:sup>\n                      Y-labeled somatostatin analogs (DOTATATE, DOTATOC, or HA-DOTATATE) between January 2004 and December 2019. Treatment response was evaluated according to the Response Assessment in Neuro-Oncology, Response Evaluation Criteria in Solid Tumors, and molecular imaging criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Most patients received 2 cycles of PRRT, and up to 4 cycles were applied. The mean total administered activity was 12.7 GBq (range: 8.5\u201328.5 GBq). Of 14 patients monitored after 2 cycles of PRRT, disease control was reached in 12 (85.7%) patients. The median progression-free survival was 32.3 months, and the median OS has yet to be reached with a median follow-up of 67.1 months. All patients tolerated the therapy without any serious acute adverse effects. No Common Terminology Criteria for Adverse Event grades 2\u20134 anemia, leukopenia, or thrombocytopenia toxicities were observed during or after PRRT. No renal toxicity, hepatotoxicity, or late radiation adverse effects were reported during long-term follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PRRT showed promising outcomes in patients with refractory meningiomas, with high disease control and encouraging progression-free survival and OS, and therefore appears to be a favorable therapeutic option. With long-term follow-up, PRRT demonstrated a favorable safety profile, resulting in very few side effects in this cohort of patients with meningioma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005845","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T01:00:16Z","timestamp":1746406816000},"page":"508-516","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-1813","authenticated-orcid":false,"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[{"name":"Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore"},{"name":"Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Academy for Precision Oncology, International Centers for Precision Oncology (ICPO), Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8379-5202","authenticated-orcid":false,"given":"Mengqi","family":"Shi","sequence":"additional","affiliation":[{"name":"Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore"},{"name":"Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2087-0347","authenticated-orcid":false,"given":"Vivianne","family":"Jakobsson","sequence":"additional","affiliation":[{"name":"Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore"},{"name":"Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Academy for Precision Oncology, International Centers for Precision Oncology (ICPO), Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-1096","authenticated-orcid":false,"given":"Harshad R.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Schuchardt","sequence":"additional","affiliation":[{"name":"THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-0075","authenticated-orcid":false,"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[{"name":"THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany"},{"name":"Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/02688697.2019.1661965","article-title":"The outcome of patients with surgically treated meningioma in England: 1999-2013. A cancer registry data analysis","volume":"33","author":"Brodbelt","year":"2019","journal-title":"Br J Neurosurg"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/neuonc\/now001","article-title":"68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate?","volume":"18","author":"Sommerauer","year":"2016","journal-title":"Neuro Oncol"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3390\/jcm11092364","article-title":"The current role of peptide receptor radionuclide therapy in meningiomas","volume":"11","author":"Fodi","year":"2022","journal-title":"J Clin Med"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0002-9440(10)65564-2","article-title":"Immunohistochemical localization of somatostatin receptors sst2A in human tumors","volume":"153","author":"Reubi","year":"1998","journal-title":"Am J Pathol"},{"key":"R10-20250613","first-page":"485","article-title":"Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?","volume":"20","author":"Barresi","year":"2008","journal-title":"Oncol Rep"},{"key":"R11-20250613","first-page":"1865","article-title":"Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A","volume":"6","author":"Schulz","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R12-20250613","first-page":"13185","article-title":"Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance","volume":"8","author":"Silva","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10143-021-01552-y","article-title":"Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential","volume":"45","author":"Behling","year":"2022","journal-title":"Neurosurg Rev"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","article-title":"90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas","volume":"56","author":"Gerster-Gilli\u00e9ron","year":"2015","journal-title":"J Nucl Med"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","article-title":"Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma","volume":"36","author":"Bartolomei","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00270-019-02262-1","article-title":"Will (177)Lu-DOTATATE treatment become more effective in salvage meningioma patients, when boosting somatostatin receptor saturation? A promising case on intra-arterial administration","volume":"42","author":"Braat","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R17-20250613","first-page":"29","article-title":"Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"22","author":"Hartrampf","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1097\/RLU.0000000000003627","article-title":"Peptide receptor radionuclide therapy in patients with neurofibromatosis type 2: initial experience","volume":"46","author":"Kertels","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1748-717X-7-99","article-title":"Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"7","author":"Kreissl","year":"2012","journal-title":"Radiat Oncol"},{"key":"R20-20250613","first-page":"193","article-title":"Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature","volume":"29","author":"Minutoli","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"R21-20250613","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"key":"R22-20250613","first-page":"1538","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2967\/jnumed.118.215848","article-title":"Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients","volume":"60","author":"Zhang","year":"2019","journal-title":"J Nucl Med"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","article-title":"THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy - the bad Berka experience","volume":"2","author":"Baum","year":"2012","journal-title":"Theranostics"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF00185857","article-title":"A new principle to normalize plasma concentrations allowing single-sample clearance determinations in both children and adults","volume":"19","author":"Bubeck","year":"1992","journal-title":"Eur J Nucl Med"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2967\/jnumed.118.223149","article-title":"177)Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney","volume":"60","author":"Zhang","year":"2019","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"R29-20250613","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-022-04148-8","article-title":"Emerging systemic treatment options in meningioma","volume":"161","author":"Mair","year":"2022","journal-title":"J Neurooncol"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"Cns72","DOI":"10.2217\/cns-2021-0003","article-title":"Meningioma: not always a benign tumor. a review of advances in the treatment of meningiomas","volume":"10","author":"Maggio","year":"2021","journal-title":"CNS Oncol"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"27848","DOI":"10.18632\/oncotarget.8425","article-title":"Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review","volume":"7","author":"Min","year":"2016","journal-title":"Oncotarget"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11060-017-2398-8","article-title":"Comparing available criteria for measuring brain metastasis response to immunotherapy","volume":"132","author":"Qian","year":"2017","journal-title":"J Neurooncol"},{"key":"R34-20250613","first-page":"234","article-title":"Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"key":"R35-20250613","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3171\/jns.2002.97.2.0341","article-title":"Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma","volume":"97","author":"Mason","year":"2002","journal-title":"J Neurosurg"},{"key":"R36-20250613","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol"},{"key":"R37-20250613","first-page":"1911","article-title":"Intraarterial administration of peptide receptor radionuclide therapy in patients with advanced meningioma: initial safety and efficacy","volume":"65","author":"Amerein","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T08:00:46Z","timestamp":1749801646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005845","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"2024-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}